Seaport Therapeutics has raised $225 million to advance its development of innovative brain drugs, focusing on longer-lasting psychiatric medications with fewer side effects. Founded by PureTech Health, the company is progressing its lead oral drug targeting major depressive disorder and exploring treatments for anxiety and neuropsychiatric disorders. The funding round, led by General Atlantic, reflects strong investor confidence in Seaport's experienced team and its promising research programs.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
